This trial will study using F-18 16 alpha-fluoroestradiol positron emission tomography/computed tomography to see if it can help predict response to endocrine therapy in patients with newly diagnosed breast cancer.
1 Primary · 8 Secondary · Reporting Duration: Up to 1 year
Experimental Treatment
99 Total Participants · 1 Treatment Group
Primary Treatment: F-18 16 Alpha-Fluoroestradiol · No Placebo Group · Phase 2
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: